ChemGenex Pharmaceuticals Limited

Regeneron Pharmaceuticals, Inc. ’s move to publicly broadcast its decision to “offer” Democratic Presidential Candidate Joe Biden’s team access to its experimental cocktail of two monoclonal antibodie

It may be one of the few downsides of personalized medicine. The Food & Drug Administration and other stakeholders are concerned that the pharmaceutical industry’s interest in developing targeted ther

Pharma dealmaking is usually fraught with all kinds of risks, whether technical, clinical, regulatory, financial, or otherwise. But Allergan Inc. ’s buyout of migraine drug developer MAP Pharmace

Promoting investigational therapies as if they are already approved by FDA may seem like a bright-line violation but even some well-respected companies have crossed it. The latest firm to receive a re